Our website uses cookies which are small bits of data stored as text files on your device. We use these cookies as described in our cookie policy. You can disable or change your cookie settings at any time but parts of our site will not function correctly without them.

IncyteCARES is a program for residents of the United States and Puerto Rico.

IncyteCARES: A Patient Assistance and Support Program IncyteCARES: A Patient Assistance and Support Program IncyteCARES: A Patient Assistance and Support Program
Copay card icon

Get enrolled in IncyteCARES!

We offer support for eligible patients during treatment, including a program that could make your copay as little as $0.*

*Terms and conditions apply. Terms of this program may change at any time.

Financial Assistance Options for Jakafi® (ruxolitinib)

IncyteCARES is committed to helping eligible patients get the medicines they need. That’s why we offer certain programs, and may be able to connect you to others, that may help make your out-of-pocket costs more affordable if you qualify. To qualify, you must meet certain eligibility requirements.

copay card

FOR ELIGIBLE PATIENTS WITH COMMERCIAL OR PRIVATE PRESCRIPTION INSURANCE
IncyteCARES COPAY/COINSURANCE PROGRAM

Eligible patients can receive Jakafi for as little as $0 per month

Image of a Patient Copay/Coinsurance Assistance Card

To qualify, you must:

  • Have commercial or private prescription drug coverage. Patients insured under federal or state government prescription drug programs—including Medicare Part D, Medicare Advantage, Medicaid, or TRICARE—are not eligible. Patients without prescription drug coverage are also not eligible
  • Be a resident of the United States or Puerto Rico
  • Have a valid prescription for Jakafi for an FDA-approved use

*Amount of savings for the purchase of Jakafi will not exceed $11,977 per month and $25,000 per year. Uninsured, cash-paying patients are not eligible. Not valid for patients insured through Medicare Part D, Medicare Advantage, Medicaid, and TRICARE or any state medical or pharmaceutical assistance program. Valid prescription for Jakafi for an FDA-approved indication is required. Please see complete Terms and Conditions or call IncyteCARES. Update effective as of September 30, 2019.

HOW TO ENROLL

Call IncyteCARES at 1-855-452-5234, Monday through Friday, 8 AM–8 PM ET.

We’ll ask you a few questions to determine your eligibility. If you are eligible, we can enroll you and get your program member number immediately. (A Copay/Coinsurance Program card will also be mailed to you separately.) If you’d like, we can contact your specialty pharmacy to provide your program information so you can begin receiving Jakafi for as little as $0 per month copay/coinsurance right away.

You can also ask your Healthcare Professional or Specialty Pharmacist to enroll you in this Copay/Coinsurance Program.

Terms and conditions apply. Terms of this program may change at any time.
Graphic representation of 2 people

FOR ELIGIBLE PATIENTS WHO ARE UNINSURED OR UNDERINSURED FOR JAKAFI
IncyteCARES PATIENT ASSISTANCE PROGRAM

Eligible patients can receive Jakafi free of charge

The IncyteCARES Patient Assistance Program (PAP) helps eligible patients who do not have prescription drug insurance or who have an insurance plan that will not cover their Jakafi treatment. No purchase contingencies or other obligations apply.

To qualify, you must:

  • Be confirmed as eligible and enrolled in IncyteCARES
  • Be a resident of the United States or Puerto Rico
  • Have a valid prescription for Jakafi for an FDA-approved use
  • Meet certain household size and annual income criteria, including earning less than $125,000 per year or less than 600% of the Federal Poverty Level (whichever amount is higher)
  • Patients with prescription coverage through government programs—including Medicare Part D, Medicare Advantage, Medicaid, TRICARE—or by a healthcare exchange plan are not eligible

HOW TO APPLY

Call IncyteCARES at 1-855-452-5234, Monday through Friday, 8 AM–8 PM ET.

To start, we’ll ask you a few questions to help determine your eligibility for this program. Based on your answers, we will notify you within 2 business days if you qualify for conditional approval. That means you’re approved for a supply of free medicine for 90 days. In the meantime, you must send us proof of your current household income. It can be one of the following: your most recent federal income tax return, your most recent W-2 earnings statement from your employer, or one month of your recent pay stubs. Once we review your income information, we’ll notify you if you are fully approved for the IncyteCARES Patient Assistance Program and can continue to receive Jakafi for free.

Terms and conditions apply. Terms of this program may change at any time.
Calendar

FOR PATIENTS WHOSE INSURANCE COVERAGE FOR JAKAFI IS DELAYED
IncyteCARES TEMPORARY ACCESS PROGRAM

Eligible patients may be able to receive a free short-term supply of Jakafi§

If you have been prescribed Jakafi for an FDA-approved use and you experience a delay in coverage, we may be able to provide a free 30-day supply of medicine. No purchase contingencies or other obligations apply.

To qualify, you must:

  • Be confirmed as eligible and enrolled in IncyteCARES
  • Have commercial or private prescription drug coverage or a healthcare exchange plan. Patients insured under federal or state government prescription drug programs—including Medicare Part D, Medicare Advantage, Medicaid, or TRICARE—are not eligible. Patients without prescription drug coverage are also not eligible
  • Be a resident of the United States or Puerto Rico
  • Have a valid prescription for Jakafi for an FDA-approved use
  • Provide proof of the submitted claim and coverage delay. This may be a notice you receive from your insurance company

TO LEARN MORE

Call IncyteCARES at 1-855-452-5234, Monday through Friday, 8 AM–8 PM ET.

§Terms and conditions apply. Terms of this program may change at any time.
hand with heart

FOR ALL PATIENTS
INFORMATION ABOUT NONPROFIT OR OTHER SUPPORT ORGANIZATIONS

Patients may be eligible for help with medicine, treatment-related travel, and other costs

If you do not qualify for our IncyteCARES Copay/Coinsurance or Patient Assistance Programs, we may be able to provide information about other organizations or independent foundations that offer support. If you’re eligible, these independent organizations sometimes provide help with your medicine costs, transportation or lodging expenses related to treatment, or counseling services offered at reduced or no cost. Eligibility and availability of these programs are determined by the individual organizations.

TO LEARN MORE

Call IncyteCARES at 1-855-452-5234, Monday through Friday, 8 AM–8 PM ET.

We can give you contact information and website addresses where you can find more information on other organizations and independent foundations that may be able to help with your specific needs.

"It was a huge relief to have the copay help. I couldn’t believe how easy it was."

– Sue W.

INDICATIONS AND USAGE

Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is also used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

IMPORTANT SAFETY INFORMATION

JAKAFI CAN CAUSE SERIOUS SIDE EFFECTS, INCLUDING:

Low blood counts: Jakafi® (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.

Increases in cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: for certain types of MF and PV – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; and for acute GVHD – low platelet, red or white blood cell counts, infections, and fluid retention.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, high cholesterol or triglycerides, had skin cancer, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.